Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Mereo BioPharma Group plcNASDAQ: MREO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $304.49K rose 12.3% year over year, ahead of the -5.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 48.5% from the prior quarter.

Context

  • Cost of revenue amounted to 26.6% of revenue in FY2025.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +12.3% holds above the trailing-twelve-month pace of -5.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$304.49K-48.5% QoQ
Last fiscal yearDec 2025
$133K-87.8% YoY
LTMMar 2026
$1.03M-5.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%——
1 year-87.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
133K USD
Year-over-year change
-87.8%
4-year CAGR
-72.8%

Cost of Revenue vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.2% is the 2nd highest of 4, against a peer median of -26.6%.
  • Cost of revenue amounts to 205.7% of revenue for MREO, versus a peer median of 21.9%.
MREO Competitors
Cost of Revenue for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M USD-26.6%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
MREOMereo BioPharma Group plcLTM Mar 2026$1.03M USD-5.2%—205.7%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$866K USD-97.1%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$546K USD———
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$79K USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding MREO) —-26.6%+68.4%21.9%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.